Researchers Link FDA Actions to Decrease in LABA Use in Asthma Treatment – Regulatory Focus


Regulatory Focus

Researchers Link FDA Actions to Decrease in LABA Use in Asthma Treatment
Regulatory Focus
A recent study finds an association between regulatory actions by the US Food and Drug Administration (FDA) and the use of long-acting ?2-agonists (LABA) commonly used to treat asthma. The study, published in the Journal of Allergy and Clinical …
Simple asthma screening test could improve care for childrenScotsman

all 2 news articles »

View full post on asthma – Google News

Asthma: LABA + Steroids Not a Winning Combo for Blacks – MedPage Today


MedPage Today

Asthma: LABA + Steroids Not a Winning Combo for Blacks
MedPage Today
Asthma exacerbations were not reduced in black adults when a long acting beta-agonist (LABA) was added to treatment with inhaled corticosteroids (ICS), a randomized trial concluded. The mean number of exacerbations was 0.42 exacerbations per …
Study compares combination treatments for black adults with asthma The JAMA EurekAlert (press release)

all 4 news articles »

View full post on asthma – Google News

LAMA LABA Uncontrolled Asthma ICS – Monthly Prescribing Reference (registration)


Monthly Prescribing Reference (registration)

LAMA LABA Uncontrolled Asthma ICS
Monthly Prescribing Reference (registration)
Long-acting muscarinic antagonists (LAMA) have been shown to reduce exacerbations of chronic obstructive pulmonary disease (COPD) and are now being considered for patients with uncontrolled asthma as add-on treatment. A review in the Cochrane …

and more »

View full post on asthma – Google News

Once Asthma is Under Control, Should LABA Tx Be Stopped? – Monthly Prescribing Reference (registration)

Once Asthma is Under Control, Should LABA Tx Be Stopped?
Monthly Prescribing Reference (registration)
Long-acting beta2-agonists (LABA) are often prescribed to adults with asthma not well controlled by inhaled corticosteroid (ICS) treatment but may carry an increased risk of serious adverse events and mortality. An article in the Cochrane Library

View full post on asthma – Google News

A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma

Condition:   Asthma
Interventions:   Drug: Fluticasone Furoate;   Drug: Vilanterol;   Drug: Fluticasone propionate;   Drug: Salmeterol;   Drug: Budesonide;   Drug: Formoterol Fumarate
Sponsor:   GlaxoSmithKline
Not yet recruiting – verified May 2015

View full post on ClinicalTrials.gov: asthma | received in the last 14 days

Blame LABA Risks in Asthma on Gene Variants? – MedPage Today


Science World Report

Blame LABA Risks in Asthma on Gene Variants?
MedPage Today
Six variants in the beta2-adrenergic receptor gene (ADRB2) found in fewer than 5% of LABA-treated asthma patients were associated with double the incidence of a related hospital admission overall compared with common variants (44% versus 22% in 12 
LABA Drugs for Asthma May Negatively Impact People With Rare Genetic Science World Report
Rare Genetic Variations May Account For Severe Reaction To LABA Drugs In RedOrbit

all 12 news articles »

View full post on asthma – Google News

LABA Withdrawal Increases Asthma-Related Impairment – Journal of the American Academy of Physician Assistants

LABA Withdrawal Increases Asthma-Related Impairment
Journal of the American Academy of Physician Assistants
(HealthDay News) – For patients with asthma controlled with a combination of an inhaled corticosteroid (ICS) and a long-acting ?2-agonist (LABA), withdrawal of the LABA once asthma is controlled correlates with increased asthma-associated impairment.

View full post on asthma – Google News

Combination of ICS and LABA appears to reduce severe asthma attacks – News-Medical.net

Combination of ICS and LABA appears to reduce severe asthma attacks
News-Medical.net
A Henry Ford Hospital study has found that using two types of common asthma medications in combination reduces severe asthma attacks. Researchers say using long-acting beta-agonists (LABAs) in fixed-dose combination with inhaled corticosteroid (ICS)

and more »

View full post on asthma – Google News